1,4,5-Substituted 1,2,3-Triazoles for Selective PXR Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The promiscuous activation of pregnane X receptor (PXR) by natural substances and xenobiotics leads to unanticipated adverse drug reactions and limited drug delivery, particularly in the context of cancer therapeutics, necessitating the development of non-toxic selective modulators to control PXR activation and improve drug metabolism and delivery.
Innovation Solution
Development of 1,4,5-substituted 1,2,3-triazole compounds that act as modulators of PXR, capable of modulating PXR activity and reducing adverse drug reactions, enhancing drug efficacy and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PXR is activated by natural substances and xenobiotics, then drug metabolism is regulated, but adverse drug reactions occur and drug delivery is limited
Solution Approach 1:
The patent modifies the chemical structure of PXR ligands by changing molecular parameters (introducing specific substituents at positions 1,4,5 of the triazole ring) to alter binding affinity and selectivity, thereby reducing promiscuous activation while maintaining therapeutic effects
Solution Approach 2:
The disclosed compounds act as intermediary modulators that selectively interact with PXR to control its activation state, serving as a bridge between the drug and the receptor to prevent unwanted downstream effects while maintaining beneficial metabolism regulation
2Reliability
If PXR is activated by various drugs, then drug metabolism is controlled, but drug delivery to the brain is decreased
Solution Approach 1:
The patent modifies molecular parameters of PXR ligands (specifically the triazole core structure and substituents) to change binding characteristics, thereby reducing PXR-mediated efflux transport at the blood-brain barrier while maintaining metabolic regulation functions
3Object-affected harmful factors
If selective PXR modulators are developed, then adverse drug reactions are decreased, but compound complexity increases
Solution Approach 1:
The patent segments the complex PXR ligand structure into a core triazole ring system with distinct substituent positions (1,4,5-substitution pattern), allowing systematic modification of specific regions to achieve selectivity without requiring complete redesign of the entire molecule
Solution Approach 2:
The patent applies local quality modification by introducing specific functional groups and substituents at particular positions (1,4,5) of the triazole ring, where each position has a specific role in determining binding affinity, selectivity, and pharmacological activity
Data Source
AI summary
The present disclosure relates to 1,4,5-substituted 1,2,3-triazoles useful as modulators of pregnane X receptor (PXR) and in the treatment of disorders associated with PXR dysfunction (e.g., disorders of uncontrolled cellular proliferation, bowel disorders). The invention further relates to uses of the disclosed compounds in decreasing adverse drug reactions such as, for example, adverse reactions associated with administration of an anticancer agent, an antibacterial agent, a non-steroidal anti-inflammatory agent, and an anticonvulsant agent. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.